-
Regeneron Pharma (REGN) 'High-Dose Eylea Data Far Exceeds Expectations, Supporting Franchise' - BMO
-
"See Interesting Upside Potential for REGN" - BMO Capital Reiterates Regeneron (REGN) at Outperform on NTLA Data
-
BMO Capital Reiterates Outperform Rating, $780 Price Target on Regeneron Pharma (REGN), Awaits Key Data from Oncology Programs
-
BMO Capital Reiterates Outperform Rating, $780 Price Target on Regeneron Pharma (REGN) Following Checkmate (CMPI) Acquisition
-
BMO Capital Reiterates Outperform Rating on Regeneron Pharma (REGN)
-
BMO Capital Reiterates Regeneron Pharma (REGN) at Outperform, "Eylea Phase 2 Data Supportive of Likely Positive Phase 3"
-
Regeneron (REGN) Results Highlight Strong Fundamentals, Focus Remains on Novel Product Readouts - BMO Capital
-
BMO Capital Assumes Regeneron Pharma (REGN) at Outperform
-
Regeneron Pharma (REGN) PT Raised to $710 at BMO Capital
-
Regeneron Pharma (REGN) PT Raised to $706 at BMO Capital
-
Regeneron Pharma (REGN) PT Raised to $669 at BMO Capital
-
UPDATE: BMO Capital Upgrades Regeneron Pharma (REGN) to Outperform
-
Regeneron Pharma (REGN) PT Raised to $352 at BMO Capital
-
Novartis' Beovu Label a Positive for Regeneron Pharma (REGN) - BMO
-
Regeneron Pharma (REGN) PT Lowered to $344 at BMO Capital
-
Regeneron Pharma (REGN) PT Lowered to $375 at BMO Capital
-
Regeneron Pharma (REGN) PT Raised to $412 at BMO Capital
-
Regeneron Pharma (REGN) PT Raised to $410 at BMO Capital
-
Pre-Open Movers 03/12: (OCLR) (ADMS) (MU) Higher; (ANTH) (SVRA) (ESPR) Lower (more...)
-
Regeneron (REGN): Sanofi Weakness Could Pressure Shares - BMO
-
Regeneron (REGN): Raising PT On High Enthusiasm For Dupixent - BMO
-
BMO Capital Maintains Market Perform Rating & $421 PT on Regeneron (REGN); Novartis RTH258 Ph3 Data Highlights Long-Term Eylea Risk
-
Regeneron Pharma (REGN) PT Raised to $421 at BMO Capital; 'Too Early to Make a Call on Dupixent Launch'
-
Regeneron Pharma (REGN) PT Raised to $412 at BMO Capital Following Approval of Dupixent in Adult Atopic Dermatitis
-
BMO Capital Starts Regeneron Pharma (REGN) at Market Perform
-
Notable Analyst Rating Changes 1/25: (RSYS) (HD) (JBHT) Upgraded; (REGN) (TWTR) (WFM) Downgraded
-
Regeneron Pharma (REGN) PT Raised to $494 at BMO Capital
-
Regeneron (REGN) PRALUEN Panel Commentary Could Result in Narrower-Than-Expected Labeling, BMO Capital Says
-
Regeneron (REGN) Halted Ahead of FDA Panel Review of Praluent
-
Regeneron (REGN) PRALUENT Briefing Docs Positive But Risk to Labeling for Statin Intolerance, BMO Capital Says
-
Notable Analyst Rating Changes 2/17: (SRPT) (MU) (CCG) Upgraded; (IMAX) (CVC) (JWN) Downgraded
-
Streetinsider.com's Hot Lunchtime Reads 11/19: (FNMA) (CLF) (TSLA) (GLD)
-
BMO Capital Lift PT on Regeneron (REGN) 33% Following New EYLEA Data
-
Regeneron (REGN) Sinks on Talk of Trend of Switching Away from EYLEA
-
Notable Analyst Rating Changes 02/13: (ANR) (ATHN) (NSPH) Upgraded; (DEPO) (REGN) (AEM) Downgraded
-
BMO Capital Downgrades Regeneron Pharma (REGN) to Market Perform
-
Regeneron (REGN) Reiterated Outperform at BMO
-
BMO Capital Upgrades Regeneron Pharma (REGN) to Outperform
-
BMO Capital Downgrades Regeneron Pharma (REGN) to Market Perform
-
Declining Lucentis Market Share Bodes Well for Regeneron's (REGN) Eylea -BMO
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform